A VISIONaerie® approach
We discover, develop and commercializefirst-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases
News HighlightsAerie Pharmaceuticals Receives Positive CHMP Opinion for Roclanda® in the ... Aerie Pharmaceuticals Initiates Phase 2b Clinical Trial of AR-15512 (TRPM8 ... Santen and Aerie Conclude Exclusive License Agreement for Rhopressa® and R...
Dec 3, 4:00 PM ET
52 - WEEK LOW/HIGH